Abstract
Objective The objective of this study was to assess the safety and preliminary efficacy of repetitive magnetic stimulation (RMS) as an intervention for dry eye syndrome, focusing on symptom reduction.
Methodology This investigation involved 22 adult participants diagnosed with moderate to severe dry eye syndrome. These individuals were subjected to RMS treatment targeting one or both eyes using the VIVEYE - Ocular Magnetic Neurostimulation System Ver 1.0 (Epitech-Mag LTD; NIH clinical trials registry #NCT03012698). A placebo-controlled group was also included for comparative analysis, with all subjects being monitored over a three-month period. The evaluation of safety encompassed monitoring changes in best corrected visual acuity, ocular pathology, and reporting of adverse events. Participant tolerance was gauged through questionnaires, measurements of intraocular pressure (IOP), Schirmer’s test, and vital signs. The efficacy of the treatment was assessed by comparing pre- and post-treatment scores on fluorescein staining (according to the National Eye Institute (NEI) grading) and patient-reported outcomes.
Results The study found no significant changes in visual acuity, IOP, or Schirmer’s test results between the RMS-treated and control groups (p<0.05), indicating RMS does not adversely affect these ocular functions. However, RMS treatment was associated with improved tear film stability (p=0.198 vs. p=0.045) and corneal health (p=0.52 vs. p=0.004), with no improvements in the control group. Initial symptom improvement was observed in both RMS-treated and placebo groups (p=0.007 vs p=0.008), suggesting RMS’s potential for treating ocular surface conditions.
Conclusion The findings of this study introduce repetitive magnetic stimulation (RMS) as a promising therapeutic option for dry eye syndrome, demonstrating its capability to promote corneal epithelium repair, enhance tear film stability, and improve subjective symptom evaluations without adversely affecting intraocular pressure, visual acuity, or tear production. This confirms the safety and suggests the efficacy of RMS therapy for dry eye conditions.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
#ClinicalTrials.gov Identifier: NCT03012698
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the national Ministry of Health (#20162621) and by the institutional Helsinki committees of Hadassah Medical Center ( #HMO-0630-16).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Meeting Presentation: The ASCRS Annual Meeting, 2019, San Diego
Conflict of Interest: No conflicting relationship exists for any author.
Data Availability
The data set generated during the current study is available from the corresponding authors on reasonable request.
